目前关于心力衰竭中三回干预的证据
Rebecca T Hahn1, Marianna Adamo2, Neil P Fam3
1Division of Cardiology, Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
JACC. Heart failure
|June 17, 2025
概括
三管吐 (TR) 恶化了心力衰竭 (HF) 患者的存活率. 较早的干预,包括通过导管的选择,可能会改善结果,但需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 膜心脏疾病 膜心脏疾病
背景情况:
- 中度至严重的三腹吐 (TR) 影响高达25%的慢性心力衰竭 (HF) 患者,随着HF的严重程度而增加.
- TR进展与HF患者的生存率下降有关.
- 人们越来越认识到HF和TR病理生理学的相互作用.
研究的目的:
- 审查关于高频TR的医疗和干预管理的不断变化的数据.
- 讨论干预时间和并发症对手术结果的影响.
- 评估跨导管三门干预 (TTVI) 对高风险患者的作用.
主要方法:
- 审查关于高频和TR管理的当前文献.
- 对隔离的三膜手术结果的分析.
- 评估新兴的跨导管三管修复和更换装置.
主要成果:
- 对TR的手术结果因干预时间和患者的并发症而异.
- 以风险分数为指导的早期手术干预可能会改善结果.
- 超导管三门干预措施可用于高风险患者,但缺乏已证明的死亡率或HF住院益处.
结论:
- 对于高频中TR的最佳时间和干预类型需要进一步调查.
- 目前用于TR的器械疗法的临床益处需要进一步研究.
- 风险分层和早期干预策略对于改善TR患者的结果至关重要.
相关概念视频
Mitral Regurgitation III: Medical Management
35
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
35
Mitral Regurgitation IV: Nursing Management
97
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
97
Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
Aortic Regurgitation III: Medical Management
53
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
53
Aortic Regurgitation IV: Nursing Management
64
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
64
Mitral Valve Prolapse II: Assessment and Management
48
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
48


